

## Adamas Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 05-Aug-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

    Pre-registration..... 11

    Phase 3 Clinical..... 18

    Phase 2 Clinical..... 25

    Discovery..... 32

[Return to Table of Contents](#)

# Adamas Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	Adamas Pharmaceuticals Inc
Parent Company Name	Adamas Pharmaceuticals Inc
Website	http://www.adamaspharma.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	5
Number of Patents as Owner	17
Number of Patents as Third Party	2
Number of Deals	5
Key Indications	Parkinsons disease,Fatigue,Movement disorder,Alzheimers disease,Influenza virus infection,Viral infection,Traumatic brain injury,Brain injury,Sleep disorder,Glaucoma,HIV associated dementia,Hepatitis C virus infection,Neuropathic pain,Respiratory syncytial virus infection
Key Target-based Actions	NMDA receptor antagonist,Inosine monophosphate dehydrogenase inhibitor,Influenza matrix protein 2 inhibitor,Exo-alpha sialidase inhibitor,Acetylcholinesterase inhibitor,Folate antagonist,Nitric oxide synthase
Key Technologies	Small molecule therapeutic,Drug combination,Oral formulation,Capsule formulation,Sustained release formulation,Oral sustained release formulation,Intravenous formulation,Systemic formulation unspecified,Controlled release formulation,Film coating,Granule,Oral quick release formulation,Pellet,Tablet formulation

## COMPANY PROFILE

### SUMMARY

Adamas Pharmaceuticals (formerly NeuroMolecular Pharmaceuticals Inc), headquartered in Emeryville, CA, was founded in 2004 and is focused on the development of controlled release, novel small molecule therapeutics called advantaged therapeutics for neurological like Alzheimer's diseases and dementia and infectious diseases like influenza.

### FINANCIAL

In April 2014, Adamas priced its IPO of 3 million common stock shares at \$16 each. The underwriters were granted a 30-day over-allotment option to purchase up to an additional 450,000 common stock shares. At that time, shares were expected to begin trading on the NASDAQ Global Market under the ticker symbol 'ADMS' on April 10, 2014 and the offering was expected to close on April 15, 2014; later that month, the offering was closed and net proceeds from the offering was estimated to be approximately \$41.5 million; later that month, the company issued 81,371 additional shares to the underwriters pursuant to the over-allotment option and raised net proceeds of approximately \$42.7 million. And the shares had begun trading on NASDAQ.

In August 2009, the company raised \$40 million from a series D financing round.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	4	6
Infectious disease	2	1	3
Respiratory disease	1	1	2
Degeneration	1	1	2
Fatigue	1	0	1
Psychiatric disorder	0	1	1
Injury	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Pre-registration	1
Phase 3 Clinical	1
Phase 2 Clinical	1
Discovery	1
No Development Reported	5

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	2	0	0	0	2
Drug - CRADA	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	1	0	1

[Return to Table of Contents](#)

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	2	4
Infectious disease	0	2
Respiratory disease	0	2

### Trials by Phase

Phase	Ongoing	All
Phase 3	2	3
Phase 2	0	3
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Gastrointestinal disease	2	0	2
Growth disorder	1	0	1
Degeneration	5	0	5
Immune disorder	6	0	6
Psychiatric disorder	5	0	5
Musculoskeletal disease	1	0	1
Ocular disease	2	0	2
Genetic disorder	1	0	1
Metabolic disorder	1	0	1

[Return to Table of Contents](#)



Neurological disease	16	0	16
Respiratory disease	5	0	5
Infectious disease	5	0	5
Injury	2	0	2
Toxicity and intoxication	2	0	2
Inflammatory disease	2	0	2
Fatigue	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis

#### memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis SNAPSHOT

Drug Name	memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis
Key Synonyms	Arimenda
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc;Actavis plc
Inactive Companies	Forest Laboratories Inc
Highest Status	Pre-registration
Active Indications	Alzheimers disease
Target-based Actions	NMDA receptor antagonist;Acetylcholinesterase inhibitor
Other Actions	Nootropic agent;Neuroprotectant
Technologies	Drug combination;Oral formulation;Capsule formulation;Oral sustained release formulation;Small molecule therapeutic
Last Change Date	31-Jul-2014

#### memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis DEVELOPMENT PROFILE

##### SUMMARY

Adamas Pharmaceuticals, presumed to be in collaboration with US licensee Actavis following its acquisition of Forest Laboratories, is developing a once-daily, fixed dose combination of an extended release form of memantine ER (Namenda XR) and donepezil, as MDX-8704 in the US and as ADS-8704 (Arimenda) in ex-US territories, for the potential treatment of moderate-to-severe dementia of the Alzheimer's type .

In March 2014, Forest submitted an NDA for the treatment of moderate-to-severe Alzheimer's dementia . In October 2013, Forest planned to launch the combination in 2015.

#### memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Actavis plc	Alzheimers disease	US	Pre-registration	01-Jul-2014
Adamas Pharmaceuticals Inc	Alzheimers disease	US	Pre-registration	04-Mar-2014
Adamas Pharmaceuticals Inc	Alzheimers disease	EU	Phase 3 Clinical	31-Dec-2013

[Return to Table of Contents](#)






**memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis DRUG NAMES**

Names	Type
ADS-8704	Research Code
Namenda XR + donepezil (extended release formulation, dementia), Adamas/ Actavis	
memantine ER + donepezil (extended release formulation, dementia), Adamas/Forest	
Namenda XR + donepezil (extended release formulation, dementia), Adamas/ Forest	
MDX-8704	Research Code
memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis	
Arimenda	Trade Name

**memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis**

**CHARTS**

[Return to Table of Contents](#)



[Return to Table of Contents](#)

## COMMENTARY

### CONSENSUS SALES INFORMATION

Consensus forecast data for Actavis, following its acquisition of Forest Laboratories, are presented. No Consensus forecast data for Adamas Pharmaceuticals are currently available.

### REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In November 2012, Forest and Adamas entered into an agreement for the development and commercialization of the Arimenda to treat moderate to severe dementia of the Alzheimer's type in the US. Forest and Adamas would collaborate on the drug's development, and Forest would have exclusive US commercialization rights [1340659]. In July 2014, Actavis acquired Forest [1574106].

### memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Dementia											
0	0	0	1	0	0	0	0	0	0	0	1

#### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	1	0	0	0	0	0	0	0	1

#### Phase Definitions

##### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

##### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

##### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



memantine ER + donepezil (extended release formulation, dementia), Adamas/Actavis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Adamas Pharmaceuticals Inc	1	0	0	0	1
Actavis plc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Actavis plc	1	0	1
Adamas Pharmaceuticals Inc	1	1	2
Adamis Pharmaceuticals Corp	1	0	1

[Return to Table of Contents](#)



Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

[Return to Table of Contents](#)

## amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas

### amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas SNAPSHOT

<b>Drug Name</b>	amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas
<b>Key Synonyms</b>	Nurelin;amantadine
<b>Originator Company</b>	Adamas Pharmaceuticals Inc
<b>Active Companies</b>	Adamas Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Fatigue;Movement disorder;Parkinsons disease;Traumatic brain injury
<b>Target-based Actions</b>	
<b>Other Actions</b>	Neuroprotectant;Nootropic agent;Antiparkinsonian
<b>Technologies</b>	Oral formulation;Capsule formulation;Sustained release formulation;Small molecule therapeutic
<b>Last Change Date</b>	08-Jul-2014

### amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEVELOPMENT PROFILE

#### SUMMARY

Adamas Pharmaceuticals is developing ADS-5102 (Nurelin), a fixed-dose, once-nightly, extended-release capsule formulation of amantadine for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD), and the company is also investigating the drug for the potential treatment of non-motor symptoms of Parkinson's disease, fatigue, including the fatigue associated with multiple sclerosis (MS), and traumatic brain injury (TBI) .,. In July 2011, a phase II/III trial was initiated for LID in PD patients; in June 2012, the trial was ongoing ; in June 2013, positive data were reported ; later that month, full data were presented. In July 2012, the drug was listed as being in pre-IND development for TBI and MS fatigue. In May 2014, the drug was expected to enter phase II/III development for TBI. In March 2011, the company was seeking for commercialization rights in the US and other ex-US markets.


### amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Movement disorder	US	Phase 3 Clinical	18-Jul-2011
Adamas Pharmaceuticals Inc	Parkinsons disease	US	Phase 3 Clinical	18-Jul-2011
Adamas Pharmaceuticals Inc	Fatigue	US	Discovery	04-Jun-2012
Adamas Pharmaceuticals Inc	Traumatic brain injury	US	Discovery	05-Jul-2012

[Return to Table of Contents](#)

**amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas**  
**CHEMICAL STRUCTURES**

CAS Registry Number:	Confidence Level:
768-94-5	2
	
Name	Type
amantadine	INN
ADS-5102	

CAS Registry Number:	Confidence Level:
	2
	
Name	Type
amantadine hydrochloride	USAN
Nurelin	Trade Name
ADS-5101	Research Code

[Return to Table of Contents](#)

## amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DRUG NAMES

Names	Type
amantadine (extended release formulation, Parkinson's disease/movement disorder), Adamas Nurelin	
	Trade Name
amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas amantadine	
	INN
ADS-5102	

## amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Movement disorder											
0	0	2	2	0	1	0	0	0	0	2	3
Parkinson's disease											
0	0	1	1	0	1	0	0	0	0	1	2

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	2	2	0	1	0	0	0	0	2	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



amantadine (extended release, Parkinson's disease/traumatic brain injury/fatigue), Adamas DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Catalent Pharma Solutions	1	0	0	0	1
Adamas Pharmaceuticals Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Adamas Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1
Formulation	1
Product	1

[Return to Table of Contents](#)



## amantadine + ribavirin (oral, influenza), Adamas

### amantadine + ribavirin (oral, influenza), Adamas SNAPSHOT

<b>Drug Name</b>	amantadine + ribavirin (oral, influenza), Adamas
<b>Key Synonyms</b>	
<b>Originator Company</b>	Adamas Pharmaceuticals Inc
<b>Active Companies</b>	Adamas Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Influenza virus infection
<b>Target-based Actions</b>	Influenza matrix protein 2 inhibitor; Inosine monophosphate dehydrogenase inhibitor
<b>Other Actions</b>	Influenza A virus replication inhibitor
<b>Technologies</b>	Drug combination; Oral formulation; Small molecule therapeutic
<b>Last Change Date</b>	06-Jul-2012

### amantadine + ribavirin (oral, influenza), Adamas DEVELOPMENT PROFILE

#### SUMMARY

Adamas Pharmaceuticals is developing ADS-8902, a fixed-dose oral combination of amantadine and ribavirin to be administered in combination with a neuraminidase inhibitor such as oseltamivir (triple-combination antiviral drug (TCAD) therapy) for the potential treatment of influenza. By August 2009, a phase II influenza A trial had been initiated in the southern hemisphere; by November 2009, the trial included sites in Australia, the US, Canada and Europe ; in June 2012, the study was completed.


### amantadine + ribavirin (oral, influenza), Adamas DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Influenza virus infection	Australia	Phase 2 Clinical	19-Aug-2009
Adamas Pharmaceuticals Inc	Influenza virus infection	Canada	Phase 2 Clinical	19-Nov-2009
Adamas Pharmaceuticals Inc	Influenza virus infection	Europe	Phase 2 Clinical	19-Nov-2009
Adamas Pharmaceuticals Inc	Influenza virus infection	US	Phase 2 Clinical	16-Sep-2009

### amantadine + ribavirin (oral, influenza), Adamas CHEMICAL STRUCTURES


[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	1
	
Name	Type
amantadine + ribavirin	

CAS Registry Number:	Confidence Level:
768-94-5	2
	
Name	Type
amantadine	INN
ADS-5102	

CAS Registry Number:	Confidence Level:
36791-04-5	1
	
Name	Type
ribavirin	INN; USAN

[Return to Table of Contents](#)

Name	Type
Ibavyr	Trade Name
Vilona	Trade Name
Viramid	Trade Name
Virazole	Trade Name
NSC-163039	Research Code
ICN-1229	Research Code
tribavirin	

### amantadine + ribavirin (oral, influenza), Adamas DRUG NAMES

Names	Type
ADS-8902	Research Code
amantadine + ribavirin	
TCAD therapy (oral, influenza), Adamas	
amantadine + ribavirin (oral, influenza), Adamas	

### amantadine + ribavirin (oral, influenza), Adamas CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Influenza virus infection											
0	0	0	0	0	1	0	1	0	0	0	2

#### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	1	0	0	0	2

[Return to Table of Contents](#)

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## amantadine + ribavirin (oral, influenza), Adamas DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart




#### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	1	0	1
Adamas Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - CRADA	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Adamas Pharmaceuticals Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

### Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	1
Formulation	1

[Return to Table of Contents](#)

## ADS-324

### ADS-324 SNAPSHOT

Drug Name	ADS-324
Key Synonyms	
Originator Company	Adamas Pharmaceuticals Inc
Active Companies	Adamas Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Viral infection
Target-based Actions	Folate antagonist
Other Actions	Antiviral
Technologies	Drug combination;Small molecule therapeutic
Last Change Date	08-Mar-2013

### ADS-324 DEVELOPMENT PROFILE

#### SUMMARY

Adamas Pharmaceuticals is investigating an anti-folate, ADS-324, a combination of undisclosed repurposed approved drugs, for the potential treatment of viral infections. In June 2012, the company planned to submit an IND.

### ADS-324 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Adamas Pharmaceuticals Inc	Viral infection	US	Discovery	26-Jun-2012

### ADS-324 DRUG NAMES

Names	Type
ADS-324	Research Code



[Return to Table of Contents](#)



ADS-324 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	1	0	1
Adamas Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

